» Articles » PMID: 36409151

The Fate of Interneurons, GABA Receptor Sub-types and Perineuronal Nets in Alzheimer's Disease

Overview
Journal Brain Pathol
Date 2022 Nov 21
PMID 36409151
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is the most common neurological disease, which is associated with gradual memory loss and correlated with synaptic hyperactivity and abnormal oscillatory rhythmic brain activity that precedes phenotypic alterations and is partly responsible for the spread of the disease pathology. Synaptic hyperactivity is thought to be because of alteration in the homeostasis of phasic and tonic synaptic inhibition, which is orchestrated by the GABA inhibitory system, encompassing subclasses of interneurons and GABA receptors, which play a vital role in cognitive functions, including learning and memory. Furthermore, the extracellular matrix, the perineuronal nets (PNNs) which often go unnoticed in considerations of AD pathology, encapsulate the inhibitory cells and neurites in critical brain regions and have recently come under the light for their crucial role in synaptic stabilisation and excitatory-inhibitory balance and when disrupted, serve as a potential trigger for AD-associated synaptic imbalance. Therefore, in this review, we summarise the current understanding of the selective vulnerability of distinct interneuron subtypes, their synaptic and extrasynaptic GABA R subtypes as well as the changes in PNNs in AD, detailing their contribution to the mechanisms of disease development. We aim to highlight how seemingly unique malfunction in each component of the interneuronal GABA inhibitory system can be tied together to result in critical circuit dysfunction, leading to the irreversible symptomatic damage observed in AD.

Citing Articles

Quantification and correlation of amyloid-β plaque load, glial activation, GABAergic interneuron numbers, and cognitive decline in the young TgF344-AD rat model of Alzheimer's disease.

Futacsi A, Rusznak K, Szarka G, Volgyi B, Wiborg O, Czeh B Front Aging Neurosci. 2025; 17:1542229.

PMID: 40013092 PMC: 11860898. DOI: 10.3389/fnagi.2025.1542229.


Differential Expression of GABA Receptor-Related Genes in Alzheimer's Disease and the Positive Regulatory Role of Aerobic Exercise-From Genetic Screening to D-gal-induced AD-like Pathology Model.

Liu Y, Peng H, Liu Q, Hao J, Tang C, Yan H Neuromolecular Med. 2025; 27(1):1.

PMID: 39752101 DOI: 10.1007/s12017-024-08821-1.


mosGraphFlow: a novel integrative graph AI model mining disease targets from multi-omic data.

Zhang H, Cao D, Xu T, Chen E, Li G, Chen Y bioRxiv. 2024; .

PMID: 39282361 PMC: 11398418. DOI: 10.1101/2024.08.01.606219.


Altered firing output of VIP interneurons and early dysfunctions in CA1 hippocampal circuits in the 3xTg mouse model of Alzheimer's disease.

Michaud F, Francavilla R, Topolnik D, Iloun P, Tamboli S, Calon F Elife. 2024; 13.

PMID: 39264364 PMC: 11392531. DOI: 10.7554/eLife.95412.


The Emerging Role of Neurosteroids: Novel Drugs Brexanalone, Sepranolone, Zuranolone, and Ganaxolone in Mood and Neurological Disorders.

Singhal M, Modi N, Bansal L, Abraham J, Mehta I, Ravi A Cureus. 2024; 16(7):e65866.

PMID: 39219949 PMC: 11364262. DOI: 10.7759/cureus.65866.


References
1.
Rey C, Robert V, Bouisset G, Loisy M, Lopez S, Cattaud V . Altered inhibitory function in hippocampal CA2 contributes in social memory deficits in Alzheimer's mouse model. iScience. 2022; 25(3):103895. PMC: 8873612. DOI: 10.1016/j.isci.2022.103895. View

2.
Bruckner G, Hausen D, Hartig W, Drlicek M, Arendt T, Brauer K . Cortical areas abundant in extracellular matrix chondroitin sulphate proteoglycans are less affected by cytoskeletal changes in Alzheimer's disease. Neuroscience. 1999; 92(3):791-805. DOI: 10.1016/s0306-4522(99)00071-8. View

3.
Shi A, Petrache A, Shi J, Ali A . Preserved Calretinin Interneurons in an App Model of Alzheimer's Disease Disrupt Hippocampal Inhibition via Upregulated P2Y1 Purinoreceptors. Cereb Cortex. 2019; 30(3):1272-1290. PMC: 7132926. DOI: 10.1093/cercor/bhz165. View

4.
Brown N, Kerby J, Bonnert T, Whiting P, Wafford K . Pharmacological characterization of a novel cell line expressing human alpha(4)beta(3)delta GABA(A) receptors. Br J Pharmacol. 2002; 136(7):965-74. PMC: 1573424. DOI: 10.1038/sj.bjp.0704795. View

5.
Sancandi M, Schul E, Economides G, Constanti A, Mercer A . Structural Changes Observed in the Piriform Cortex in a Rat Model of Pre-motor Parkinson's Disease. Front Cell Neurosci. 2019; 12:479. PMC: 6296349. DOI: 10.3389/fncel.2018.00479. View